

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equality issues have been raised.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

The manufacturer stated, at the time of its submission, that there was no NICE guidance relating to the treatment of macular oedema secondary to RVO. However, positive guidance has since been issued in Technology appraisal no. 229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to RVO (May 2011).

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice

for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes. Paragraph 4.25 of the Appraisal consultation document.

Approved by Associate Director (name): Frances Sutcliffe

Date: 26/08/2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

No

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes. In section 4.26, the Final Appraisal Determination document.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 20/03/2013